Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Anthracyclines and Trastuzumab Cardiotoxicity Risk

J Clin Oncol; ePub 2016 Jul 25; Guenancia, et al

Publish date:: August 30, 2016

Women with breast cancer who are overweight or obese are at risk for cardiotoxicity when taking anthracyclines or sequential anthracyclines and trastuzumab, according to a meta-analysis of 15 studies involving more than 8,700 individuals. Among the findings:

• Those with BMI >25 kg/m²were 38% more likely to develop cardiotoxicity.

• The odds were increased by 47% for those considered obese, and 15% in those considered overweight.

• The links remained whether anthracyclines were used alone or sequentially with trastuzumab.

The authors noted that they could not separate how CV risk factors such as diabetes and hypertension contributed to cardiotoxicity.

Citation: Guenancia C, Lefebvre A, Cardinale D, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis. [Published online ahead of print July 25, 2016]. J Clin Oncol. doi:10.1200/JCO.2016.67.4846.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,